Full Press Release Details
The webinar will explore PC111, a novel monoclonal antibody drug candidate with the potential to transform the treatment landscape for Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN).
SCNI Positive Sentiment
Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases
Key Takeaway: Scinai Immunotherapeutics is set to host a webinar on May 7, 2025, to discuss PC111, a novel monoclonal antibody drug candidate. This drug has the potential to transform treatment for Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. The webinar will focus on the unmet needs in these conditions and how PC111 could address them.
Price reaction · baseline $2.6384 (2025-04-30 close) · hit pre-market · clean, no other SCNI news in the window
day 0 close · peak
+5%
Market Sentiment Analysis
POSITIVE FACTORS
- PC111 shows promise for treating severe skin diseases.
- The webinar aims to address significant unmet medical needs.
- Scinai's collaboration with Pincell highlights innovation in biopharma.
Frequently Asked Questions
What is the focus of the upcoming Scinai webinar?
The webinar will focus on PC111, a novel monoclonal antibody for treating Pemphigus Vulgaris and SJS/TEN.
When is the Scinai webinar scheduled?
The Scinai webinar is scheduled for May 7, 2025, at 11:30 AM EST.
What diseases does PC111 target?
PC111 targets Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.
Who is collaborating with Scinai on PC111?
Pincell is collaborating with Scinai on the development of PC111.